Latest
nasdaq.com Market update
Pharming Launches Joenja In Japan For APDS
(RTTNews) - Pharming Group (PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for adult and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in NHI price list. Activated PI3K delta syndrome (APDS) is a rare primary immunodeficiency caused by genetic variants in the PI3Kd (phosphoinositide 3-kinase delta) pathway, leading to …
Main company
🇳🇱 Netherlands
Read at nasdaq.com